Exenatide vs Ipilimumab

Exenatide vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Exenatide and Ipilimumab.

Mechanism of Action

Exenatide: Synthetic exendin-4 GLP-1 receptor agonist enhancing glucose-dependent insulin secretion.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Exenatide — 2.4 hours; Ipilimumab — 14.7 days.

Chemical Properties

Type: Exenatide — Protein; Ipilimumab — Antibody.